Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRC 4186

Drug Profile

TRC 4186

Alternative Names: TRC-4186; TX-41XX

Latest Information Update: 23 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic complications; Heart failure

Most Recent Events

  • 23 Feb 2018 TRC 4186 is still in phase II trials for Diabetic complications and Heart failure (Torrent Pharma pipeline, February 2018)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Diabetic complications/Heart failure associated with hyperglycaemia/diabetes (Adjunctive treatment) in India, Netherlands, Russia, Serbia, United Kingdom (PO)
  • 11 Apr 2012 Torrent Pharmaceuticals completes a phase II trial in India, the Netherlands, Russia, Serbia, and the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top